Advertisement

Topics

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

03:44 EDT 29 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) (LON/STO/NYSE: AZN) today announce that they have initiated a global pivotal Phase III, open-label, randomized multi-cent...

Other Sources for this Article

Chi-Med
Investor Enquiries
Christian Hogg, CEO
+852 2121 8200
or
U.K. & International Media Enquiries
Citigate Dewe Rogerson
Anthony Carlisle,
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
or
U.S. Based Media Enquiries
BMC Communications
Brad Miles,
+1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com
or
Susan Duffy,
+1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com
or
Investor Relations
Matt Beck, The Trout Group
+1 (917) 415 1750 (Mobile)
mbeck@troutgroup.com
or
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedr.co.uk
or
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 (20) 7886 2500

NEXT ARTICLE

More From BioPortfolio on "Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...